You may also like
Diabetes Clinical Trials: Helped or Hindered by the Current Shift in Regulatory Requirements
The potential for some agents to increase the risk of cardiovascular events has led to substantial changes in regulatory requirements for new anti-diabetic therapies. These requirements, while key to ensuring the cardiovascular safety of new agents, fail to emphasize the need to show clinical benefits, such as less visual impairment, less need for dialysis, or fewer cardiovascular events and deaths.
1 min read
Improvement Required In Hypertension Management
Seventy-five percent of the estimated 50 million adults with hypertension in the United States are at increased risk for vascular disorders, according […]
1 min read
Aprotinin Decreases the Incidence of Cognitive Deficit Following CABG and Cardiopulmonary Bypass: A Pilot Randomized Controlled Study
Purpose: Cognitive deficit after coronary artery bypass surgery (CABG) has a high prevalence and is persistent. Meta-analysis of clinical trials demonstrates a […]
1 min read